The RSI Oscillator for ALVO moved out of oversold territory on October 26, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In 27 of the 34 cases the stock moved higher. This puts the odds of a move higher at 79%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 64 cases where ALVO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on ALVO as a result. In 66 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.
The Moving Average Convergence Divergence (MACD) for ALVO just turned positive on November 10, 2026. Looking at past instances where ALVO's MACD turned positive, the stock continued to rise in 34 of 48 cases over the following month. The odds of a continued upward trend are 71%.
Following a +4.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALVO advanced for three days, in 199 of 270 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
ALVO moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ALVO crossed bearishly below the 50-day moving average on October 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The Aroon Indicator for ALVO entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-9.057) is normal, around the industry mean (6.379). P/E Ratio (-7.839) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (3.071) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 54 (best 1 - 100 worst), indicating steady price growth. ALVO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The RSI Oscillator for OPTH moved into overbought territory on November 10, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 66 cases where OPTH's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for OPTH just turned positive on November 10, 2026. Looking at past instances where OPTH's MACD turned positive, the stock continued to rise in 42 of 56 cases over the following month. The odds of a continued upward trend are 75%.
Following a +13.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where OPTH advanced for three days, in 172 of 201 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
OPTH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OPTH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for OPTH entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.760) is normal, around the industry mean (6.379). P/E Ratio (-1.164) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (135.135) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. OPTH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 70 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OPTH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
ALVO | ||
|---|---|---|
OUTLOOK RATING 1..100 | 66 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 7 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 54 | |
P/E GROWTH RATING 1..100 | 98 | |
SEASONALITY SCORE 1..100 | 65 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| ALVO | OPTH | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 79% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 72% | 2 days ago 82% |
| Momentum ODDS (%) | 2 days ago 67% | N/A |
| MACD ODDS (%) | 2 days ago 71% | 2 days ago 75% |
| TrendWeek ODDS (%) | 2 days ago 69% | 2 days ago 81% |
| TrendMonth ODDS (%) | 2 days ago 79% | 2 days ago 90% |
| Advances ODDS (%) | 8 days ago 74% | 7 days ago 86% |
| Declines ODDS (%) | 10 days ago 79% | 9 days ago 87% |
| BollingerBands ODDS (%) | N/A | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 77% | 2 days ago 90% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALVO’s FA Score shows that 1 FA rating(s) are green while OPTH’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALVO’s TA Score shows that 5 TA indicator(s) are bullish while OPTH’s TA Score has 5 bullish TA indicator(s).
ALVO (@Pharmaceuticals: Generic) experienced а +7.49% price change this week, while OPTH (@Pharmaceuticals: Generic) price change was +6.87% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.20%. For the same industry, the average monthly price growth was -6.54%, and the average quarterly price growth was +10.31%.
ALVO is expected to report earnings on Nov 11, 2026.
OPTH is expected to report earnings on Nov 13, 2026.
A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
A.I.dvisor tells us that ALVO and EBS have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ALVO and EBS's prices will move in lockstep.
| Ticker / NAME | Correlation To ALVO | 1D Price Change % | ||
|---|---|---|---|---|
| ALVO | 100% | +4.05% | ||
| EBS - ALVO | 30% Poorly correlated | -0.82% | ||
| CRON - ALVO | 24% Poorly correlated | -3.67% | ||
| PAHC - ALVO | 22% Poorly correlated | +0.09% | ||
| ACB - ALVO | 22% Poorly correlated | -0.97% | ||
| LFCR - ALVO | 21% Poorly correlated | N/A | ||
More | ||||
A.I.dvisor tells us that OPTH and GELS have been poorly correlated (+8% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that OPTH and GELS's prices will move in lockstep.
| Ticker / NAME | Correlation To OPTH | 1D Price Change % | ||
|---|---|---|---|---|
| OPTH | 100% | -9.80% | ||
| GELS - OPTH | 8% Poorly correlated | -6.12% | ||
| GLAS - OPTH | 6% Poorly correlated | +2.60% | ||
| AKAN - OPTH | 4% Poorly correlated | -8.85% | ||
| HLN - OPTH | 3% Poorly correlated | +1.00% | ||
| ALVO - OPTH | 3% Poorly correlated | +4.05% | ||
More | ||||